Genmab wisely chose not to pursue GEN3014 further, focusing instead on its existing pipeline projects. Click here to read an ...

William Blair upped their FY2028 EPS estimates for Genmab A/S in a research note issued on Monday, March 10th. William Blair ...

The NJEDA Board approved tax credits under the Emerge Program to support Sun Pharmaceutical Industries Inc.’s plan to open a new ...

Voyager Therapeutics (NASDAQ:VYGR – Get Free Report)‘s stock had its “outperform” rating reissued by analysts at Wedbush in a ...